Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3151-3160

  Sato, Akiko ^a   Itcho, Naoki ^a   Ishiguro, Hitoshi ^b,c   Okamoto, Daiki ^a   Kobayashi, Naohito ^b   Kawai, Kazuaki ^d   Kasai, Hiroshi ^d   Kurioka, Daisuke ^a   Uemura, Hiroji ^b   Kubota, Yoshinobu ^b   Watanabe, Masatoshi ^a  

^a YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Docetaxel; Magnetic nanoparticles; Prostate cancer; Reactive oxidative species

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNETIC NANOPARTICLE; REACTIVE OXYGEN METABOLITE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTINEOPLASTIC AGENT; DEOXYGUANOSINE; DNA; MAGNETITE NANOPARTICLE; TAXOID; 8 OXO 7 HYDRODEOXYGUANOSINE; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL COUNT; CELL DEATH; CELL LEVEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; DRUG EFFECT; REACTIVE OXIDATIVE SPECIES;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYGUANOSINE; DNA; HUMANS; MAGNETITE NANOPARTICLES; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TAXOIDS;

DOCETAXEL; MAGNETIC NANOPARTICLES; PROSTATE CANCER; REACTIVE OXIDATIVE SPECIES;

EID: 84880774015     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40766     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Tabata N, Ohno Y, Matsui R, et al. Partial cancer prevalence in Japan up to 2020: estimates based on incidence and survival data from population-based cancer registries. Jpn J Clin Oncol. 2008;38(2):146-157.
3. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005;23(1):1-9.
4. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control. 2004;11(6):364-373.
5. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;22(3):263-267.
6. Tannock IF, de Wit R, Berry WR, et al; for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
8. Niraula S, Tannock IF. Broadening horizons in medical management of prostate cancer. Acta Oncol. 2011;50 Suppl 1:141-147.
9. Lee SY, Cho JS, Yuk DY, et al. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J Pharmacol Sci. 2009;111(2):124-136.
10. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010; 15(19-20):842-850.
11. Shubayev VI, Pisanic TR 2nd, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61(6):467-477.
12. Cheng J, Wu W, Chen B., et al. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomedicine. 2009;4:209-216.
13. Wang C, Zhang H, Chen B, Yin H, Wang W. Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles. Int J Nanomedicine. 2011;6:1929-1935.
14. Zhang G, Ding L, Renegar R, et al. Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions. Cancer Sci. 2011;102(6):1216-1222.
15. Sato A, Tamura Y, Sato N, et al. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release. Cancer Sci. 2010;101(9): 1939-1946.
16. Kawai K, Li YS, Kasai H. Accurate measurement of 8-OH-dG and 8-OH-Gua in mouse DNA, urine and serum: effects of X-ray irradiation. Genes and Environment. 2007;29(3):107-114.
17. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010;21(11): 2135-2144.
18. Harada M, Iwata C, Saito H, et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomedicine. 2012;7: 2713-2727.
19. Ren Y, Zhang H, Chen B, et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine. 2012;7:2261-2269.
20. Aljarrah K, Mhaidat NM, Al-Akhras MA, et al. Magnetic nanoparticles sensitize MCF-7 breast cancer cells to doxorubicin-induced apoptosis. World J Surg Oncol. 2012;10:62.
21. Karlsson HL, Cronholm P, Gustafsson J, Möller L. Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res Toxicol. 2008;21(9):1726-1732.
22. Ma P, Luo Q, Chen J, et al. Intraperitoneal injection of magnetic Fe3O4- nanoparticle induces hepatic and renal tissue injury via oxidative stress in mice. Int J Nanomedicine. 2012;7:4809-4818.
23. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro. 2005;19(7):975-983.
24. Naqvi S, Samim M, Abdin M, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine. 2010;5:983-989.
25. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008;7(12):1875-1884.
26. Chen Y, Wang J, Fraig MM, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001;61(10):4112-4121.
27. Trzeciak AR, Nyaga SG, Jaruga P, Lohani A, Dizdaroglu M, Evans MK. Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. Carcinogenesis. 2004;25(8):1359-1370.
28. Chaiswing L, Bourdeau-Heller JM, Zhong W, Oberley TD. Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness. Free Radic Biol Med. 2007; 43(2):202-215.
29. Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV. Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle. 2009;8(10):1559-1566.
30. Jain G, Cronauer MV, Schrader M, Möller P, Marienfeld RB. NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol. 2012;30(3):303-310.
31. Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/ PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer. 2010;102(7):1163-1173.
32. MacKenzie L, McCall P, Hatziieremia S, et al. Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Hum Pathol. 2012;43(9):1491-1500.
33. Jing H, Wang J, Yang P, Ke X, Xia G, Chen B. Magnetic Fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells. Int J Nanomedicine. 2010;5:999-1004.
34. Marano F, Hussain S, Rodrigues-Lima F, Baeza-Squiban A, Boland S. Nanoparticles: molecular targets and cell signalling. Arch Toxicol. 2011;85(7):733-741.